USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
MIDI, INC.
Address:
MIDI, INC.
125 SANDY DR
NEWARK, DE 19713
Phone:
N/A
URL:
N/A
EIN:
510339655
DUNS:
804737278
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $483,154.00 6
SBIR Phase II $1,613,277.00 3

Award List:

RAPID INEXPENSIVE ASSAY FOR TB AND OTHER MYCOBACTERIA

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$94,964.00
Agency:
HHS
Principal Investigator:
Sasser, myron
Abstract:
N/a

N/A

Award Year / Program / Phase:
1999 / SBIR / Phase II
Award Amount:
$529,855.00
Agency:
HHS
Principal Investigator:
Sasser myron
Abstract:
N/a

IDENTIFICATION OF BACTERIA DIRECT FROM BLOOD CULTURE

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$94,474.00
Agency:
HHS
Principal Investigator:
Myron Sasser
Abstract:
Not Available There is a need for a fundamentally sound and experimentally validated methodology and software for life prediction for ceramic matrix composite (CMC) propulsion system components and attachments with environmental barrier coatings (EBCs). The present proposal is for a reserach and… More

IDENTIFICATION OF BACTERIA DIRECT FROM BLOOD CULTURE

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Myron Sasser
Abstract:
DESCRIPTION (Verbatim from Applicant's Abstract):Rapid identification of bacteria direct from a blood culture bottle would speed up patient treatment and recovery, thereby also greatly reducing hospital care costs. The current procedure of subculturing typically takes… More

IDENTIFICATION OF BACTERIA DIRECT FROM BLOOD CULTURE

Award Year / Program / Phase:
2001 / SBIR / Phase II
Award Amount:
$317,465.00
Agency:
HHS
Principal Investigator:
Myron Sasser
Abstract:
DESCRIPTION (Verbatim from Applicant's Abstract):Rapid identification of bacteria direct from a blood culture bottle would speed up patient treatment and recovery, thereby also greatly reducing hospital care costs. The current procedure of subculturing typically takes… More

Nosocomial infections: Automated typing and data mining

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$97,560.00
Agency:
HHS
Principal Investigator:
Myron Sasser
Abstract:
DESCRIPTION (provided by applicant): Nosocomial infections cause about 90,000 deaths annually in the U.S. and have an associated medical care cost of about 3.5 billion dollars. Despite being the fourth leading cause of death, there has been limited development of rapid, integrated… More

Rapid Susceptibility Testing of MDR M. tuberculosis

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$97,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This Phase I research will test the feasibility of using mycolic acid analysis as a very rapid test for drug susceptibility of Mycobacterium tuberculosis. The significance of TB is evident in that more than one-third of the world's population is infected by M.… More

Rapid Susceptibility Testing of MDR M. tuberculosis- Phase II

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$765,957.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long-term objective of this project is the development of a system based on high performance liquid chromatography (HPLC) for rapid and accurate antibiotic susceptibility testing of Mycobacterium tuberculosis (MTB). Susceptible and resistant strains of MTB,… More

Prevention of Clostridium difficile-associated disease

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$99,156.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Clostridium difficile-associated disease (CDAD) is a hospital-acquired problem following routine antibiotic treatment. Its impact may exceed that of any other nosocomial infection. Spores of the toxin-producing pathogen are highly resistant to antibiotics and… More